Today's Rundown Featured Story | | | Wednesday, April 8, 2020 AstraZeneca has outlined its multipronged approach to the development of antibodies against the pandemic SARS-CoV-2 virus. The Big Pharma is applying its own discovery capabilities to the task and helping to evaluate candidates identified by academic partners in China and the U.S. |
|
|---|
|
Top Stories Tuesday, April 7, 2020 Genentech, which could bring the third spinal muscular atrophy treatment to market in just over three years, must wait a little longer. Since the FDA promised risdiplam a speedy review in November, the company has submitted more data, leading the agency to extend its review deadline to Aug. 24. Wednesday, April 8, 2020 Clinical trial enrollment has dropped massively across the world as endocrine, cardiovascular tests being the hardest hit. Wednesday, April 8, 2020 Arrakis Therapeutics has been dodging pharma suitors since its early days, keeping its head down and “politely declining” advances “because we weren’t ready.” Now, the biotech has enlisted Roche to help develop a suite of RNA-targeted small-molecule drugs in a deal with a $190 million upfront price tag but that could end up worth billions more. Wednesday, April 8, 2020 Keros Therapeutics has braved a turbulent market to pull off an IPO, hitting the top end of its price range and selling 20% more shares than originally planned. The upsized IPO gives Keros the firepower to take two drugs into phase 2 in a clutch of hematological and musculoskeletal indications. Wednesday, April 8, 2020 “None of the tests we have validated would meet the criteria for a good test," said the University of Oxford's Sir John Bell, citing many false positive and false negative results, and describing an accurate test as potentially weeks away. Wednesday, April 8, 2020 Scientists have been using viruses to deliver gene therapies or vaccines. Now, researchers at the University of Iowa and the University of Georgia are suggesting the virus that causes kennel cough in dogs could be used in the construct of vaccines against COVID-19. Resources Sponsored by: Clinical Ink This white paper includes a Phase III case study and discusses BYOD advantages and misconceptions, regulatory, copyright, and equivalency considerations. Sponsored by: Research Solutions Turn your drug failures into competitive advantage. Sponsored by: ICON How will US payers evaluate and manage digital therapeutics? Get insights and recommendations on successful market access considerations. Sponsored by: Epsilon Download this e-book to learn 9 ways to enhance the customer experience within healthcare marketing. Sponsored by: Copyright Clearance Center Despite advances in content aggregation and search, silos still limit the free flow of data and analytics. So, what can be done, and how can you get more value from the data you already have? Sponsored by: Applied BioMath Learn how we used a tiered model-based approach of a bispecific antibody to appropriately cover multiple antigen pairs to help teams with informed antibody design, prioritization of experiments, and triaging of challenging antigen pairs Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Outer Edge Technology To survive in these challenging conditions, companies need to promptly address business continuity issues - especially the remote delivery of data and voice solutions. See how Outer Edge can help. Sponsored by: Patheon, by Thermo Fisher Scientific Poorly soluble molecules hindering your workflow? Sponsored by: eClinical Solutions Key findings from the 2019 Life Sciences Data & Analytics Survey conducted by the Tufts Center for the Study of Drug Development will be unveiled during this live webinar led by industry expert and study lead, Ken Getz, Director of Sponsored Programs and Associate Professor. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Clarify Health Pharma launch teams spend significant resources on data and analytics with limited ROI. Read this case study to learn how a Life Sciences company identified two times more patients best suited for therapy, using Clarify’s deep and longitudinal patient and HCP insights. | 
